Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATAI LIFE SCIENCES N.V.

(ATAI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
12.58(c) 12.43(c) 12.76(c) 12.97(c) 13.5(c) Last
220 425 141 694 176 992 144 129 174 526 Volume
+0.24% -1.19% +2.65% +1.65% +4.09% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 18,1 M - -
Net income 2021 -120 M - -
Net cash position 2021 383 M - -
P/E ratio 2021 -16,0x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -161 M - -
Net cash position 2022 376 M - -
P/E ratio 2022 -13,3x
Yield 2022 -
Capitalization 2 090 M 2 090 M -
EV / Sales 2021 94,3x
EV / Sales 2022 -
Nbr of Employees 35
Free-Float 90,3%
More Financials
Company
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The company is aiming to transform the treatment of mental health disorders. 
More about the company
All news about ATAI LIFE SCIENCES N.V.
10/11ATAI LIFE SCIENCES N : Chymia Form Precision Psychiatry Company to Develop Targeted Depres..
MT
10/11ATAI LIFE SCIENCES N : announces the launch of PsyProtix, to develop a precision psychiatr..
AQ
10/11Atai Life Sciences Announces the Launch of Psyprotix, to Develop A Precision Psychiatry..
CI
10/05Asian ADRs Move Higher in Tuesday Trading
MT
10/01Asian ADRs Sharply Lower Friday as China Education Stocks Slide
MT
09/21ATAI LIFE SCIENCES N : Unit Starts Dosing in Phase 1/2a Trial of Ibogaine in Opioid Use Di..
MT
09/21ATAI LIFE SCIENCES N : DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogain..
AQ
09/15ATAI LIFE SCIENCES N : Increases Loan in Principal by US$6m to Support IntelGenx's Graduat..
AQ
09/14ATAI LIFE SCIENCES N : ' Perception Neuroscience Initiates Phase 2a Study of PCN-101 to Tr..
MT
09/14ATAI LIFE SCIENCES N : Perception Neuroscience initiates Phase 2a study of PCN-101 (R-keta..
AQ
09/09atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeuti..
GL
09/09Atai Life Sciences and Introspect Digital Therapeutics to Test Novel Digital Therapeuti..
CI
09/03ATAI LIFE SCIENCES N : to Participate in Upcoming September Investor Conferences
AQ
09/01ATAI LIFE SCIENCES N : Jefferies Starts Atai Life Sciences at Buy with $27 Price Target
MT
08/20ATAI LIFE SCIENCES N : Management's Discussion and Analysis of Financial Condition and Res..
AQ
More news
News in other languages on ATAI LIFE SCIENCES N.V.
10/11Atai Life Sciences et Chymia créent une société de psychiatrie de précision pour dévelo..
10/05Les ADR asiatiques en hausse mardi
10/01Les ADR asiatiques ont fortement baissé vendredi en raison de la chute des valeurs éduc..
09/21Atai Unit commence le dosage dans le cadre de l'essai de phase 1/2a sur l'ibogaïne dans..
09/14Perception Neuroscience, filiale d'Atai Life Sciences, lance une étude de phase 2a sur ..
More news
Analyst Recommendations on ATAI LIFE SCIENCES N.V.
More recommendations
Chart ATAI LIFE SCIENCES N.V.
Duration : Period :
Atai Life Sciences N.V. Technical Analysis Chart | ATAI | NL0015000DX5 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 13,50 $
Average target price 29,10 $
Spread / Average Target 116%
EPS Revisions
Managers and Directors
Florian Brand Chief Executive Officer
Gregory L. Weaver Chief Financial Officer
Srinivas G. Rao Chief Scientific Officer
Rolando Gutíerrez-Esteinou Chief Medical Officer
Alexis Marc Joel Louis de Rosnay Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ATAI LIFE SCIENCES N.V.0.00%2 090
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414